Ignite Creation Date:
2025-12-24 @ 10:46 PM
Ignite Modification Date:
2025-12-29 @ 5:30 AM
Study NCT ID:
NCT05362669
Status:
UNKNOWN
Last Update Posted:
2022-05-05
First Post:
2022-05-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SMS Messaging for Invitation in the Cervical Cancer Screening Programme
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002583', 'term': 'Uterine Cervical Neoplasms'}], 'ancestors': [{'id': 'D014594', 'term': 'Uterine Neoplasms'}, {'id': 'D005833', 'term': 'Genital Neoplasms, Female'}, {'id': 'D014565', 'term': 'Urogenital Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D002577', 'term': 'Uterine Cervical Diseases'}, {'id': 'D014591', 'term': 'Uterine Diseases'}, {'id': 'D005831', 'term': 'Genital Diseases, Female'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D000091662', 'term': 'Genital Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Invitation to cervical cancer screening using SMS compared to telephone call invitation.'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 450}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2021-11-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2022-05', 'completionDateStruct': {'date': '2022-12-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2022-05-02', 'studyFirstSubmitDate': '2022-05-02', 'studyFirstSubmitQcDate': '2022-05-02', 'lastUpdatePostDateStruct': {'date': '2022-05-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-05-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-05-31', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Participation in cervical cancer screening program', 'timeFrame': '12 weeks', 'description': 'Participation (no/yes) in cervical cancer screening program will be gathered prospectively 12 weeks after sending the screening invitation (day 0).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Screening', 'Self-sampling'], 'conditions': ['Cervical Cancer', 'Human Papilloma Virus']}, 'descriptionModule': {'briefSummary': 'A study on two different methods of invitation to participate to the cervical cancer screening programme will be conducted within a demonstration project to switch from cytology-based screening to HPV-based screening using self-sampling delivered through the network of pharmacy offices among regular screening attendants in the Barcelona Metropolitana Sud Area, in Catalonia.\n\nAt the moment, eligible women are invited to participate to cervical cancer screening via a telephone call invitation explaining the new self-sampling method. Invitation via SMS containing a link to a webpage with information on most frequent questions might be an adequate alternative method that would save costs and workload on human resources.\n\nThe aim of this study is to assess the impact on cervical cancer screening participation of an invitation method based on text messaging (SMS).\n\nThe invitation method will be evaluated through an interventional trial, in which we will compare the invitation to cervical cancer screening using SMS versus a telephone call invitation explaining the new self-sampling method.', 'detailedDescription': 'Main Hypothesis:\n\nThe use of direct SMS without an explanatory call for cervical cancer screening invitation is an acceptable option to invite women if the participation obtained is more than 70% and not less than 15% of the call (current practice).\n\nSpecific Hypothesis:\n\n* Participation in cervical cancer screening programme using SMS invitation is non-inferior to 70%.\n* Participation in cervical cancer screening programme using telephone call is non-inferior to 70%.\n* Participation using SMS invitation is non-inferior to participation using telephone call invitation, considering that an absolute difference less than 15% may not be clinically relevant.\n\nSample size calculation:\n\nA one-sample non-inferiority test for calculating sample size was performed, assuming a participation rate of 80% using SMS invitation and 85% using telephone call invitation in the cervical cancer screening programme. To detect a participation rate using SMS or telephone call invitation non-inferior to 70%, with a margin of 5%, accepting an alpha risk of 0.025 and a beta risk of 0.2, and 5% of loses of follow-up, we will need 27 women in the telephone call group and 59 women in the SMS group. To observe this non-inferiority by age group (≤40 years, 41-54 years, ≥55 years), 27 and 59 women will be needed for each age group.\n\nTo compare both study arms, a two-sample non-inferiority test was performed assuming that using SMS messages to invite women to participate in cervical cancer screening programme will be 5% lower compared to participation when invitation is performed by a phone call (80% versus 85% respectively), although this difference will be non-inferior to 15-15.5%. Thus, if there is a true difference in favor of the telephone call group of 5%, assuming 5% of loses of follow-up, then 450 women will be required (225 in each arm) to be 80% sure that the upper limit of a one-sided 97.5% confidence interval will exclude a difference in favor of the SMS group of more than 15-15.5%.\n\nRandomization procedure:\n\nWomen will be randomized in two study arms: intervention (SMS message invitation) and control (telephone call invitation). Randomization will be performed based on permuted blocks of 6 women to ensure equal distribution among age groups.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '35 Years', 'genderBased': True, 'genderDescription': 'Only women participate in cervical cancer screening programme', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Eligible women for cervical cancer screening aged 30 to 65 years of age.\n* Registered at the Health Care Database (RCA).\n\nExclusion Criteria:\n\n* Individuals without a mobile phone number registered at the RCA.'}, 'identificationModule': {'nctId': 'NCT05362669', 'acronym': 'CERCA-SMS', 'briefTitle': 'SMS Messaging for Invitation in the Cervical Cancer Screening Programme', 'organization': {'class': 'OTHER', 'fullName': "Institut Català d'Oncologia"}, 'officialTitle': 'SMS Messaging for Invitation in the HPV-based Cervical Cancer Screening Programme in Catalonia (CERCA-SMS Study)', 'orgStudyIdInfo': {'id': 'OTC21-01'}, 'secondaryIdInfos': [{'id': 'PR271/11', 'type': 'OTHER', 'domain': 'Independent Review Board Hospital Universitary de Bellvitge'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Experimental - Intervention', 'description': 'SMS invitation to participate in cervical cancer screening using HPV self-sampling.', 'interventionNames': ['Behavioral: SMS invitation']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Active Comparator - Usual Care', 'description': 'Phone call invitation to participate in cervical cancer screening using HPV self-sampling.', 'interventionNames': ['Behavioral: Phone call invitation']}], 'interventions': [{'name': 'SMS invitation', 'type': 'BEHAVIORAL', 'description': 'Behavioral: SMS to invite to cervical cancer screening using HPV self-sampling.', 'armGroupLabels': ['Experimental - Intervention']}, {'name': 'Phone call invitation', 'type': 'BEHAVIORAL', 'description': 'Behavioral: Phone call to invite to cervical cancer screening using HPV self-sampling.', 'armGroupLabels': ['Active Comparator - Usual Care']}]}, 'contactsLocationsModule': {'locations': [{'zip': '08908', 'city': "L'Hospitalet de Llobregat", 'state': 'Catalunya, Spain', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Paula Peremiquel-Trillas, MD MPH PhDc', 'role': 'CONTACT', 'email': 'paula.peremiquel@iconcologia.net', 'phone': '+34932607812', 'phoneExt': '3118'}, {'name': 'Esther Roura Fornells, MPH PhD', 'role': 'CONTACT', 'email': 'eroura@iconcologia.net', 'phone': '+34932607812', 'phoneExt': '3185'}, {'name': 'Paula Peremiquel-Trillas, MD, MPH, PhDc', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Esther Roura Fornells, MPH, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Laia Bruni Coccoz, MD, MPH, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Clàudia Robles Hellín, MPH, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Raquel Ibáñez, MPH, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Laura Monfil, BSc', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Maite Carvajal, RN', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Rebeca Font', 'role': 'SUB_INVESTIGATOR'}], 'facility': "Institut Català d'Oncologia", 'geoPoint': {'lat': 41.35967, 'lon': 2.10028}}], 'centralContacts': [{'name': 'Paula Peremiquel-Trillas, MD, MPH, PhDc', 'role': 'CONTACT', 'email': 'paula.peremiquel@iconcologia.net', 'phone': '+34932607812', 'phoneExt': '3118'}, {'name': 'Esther Roura Fornells, MPH, PhD', 'role': 'CONTACT', 'email': 'eroura@iconcologia.net', 'phone': '+34932607812', 'phoneExt': '3185'}], 'overallOfficials': [{'name': 'Paula Peremiquel-Trillas, MD, MPH, PhDc', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Institut Català d'Oncologia"}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': "Institut Català d'Oncologia", 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}